NCT06574789View on ClinicalTrials.gov

Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

October 29, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2028

Conditions
Cytomegalovirus Viraemia
Interventions
DRUG

Standard dosing of IV ganciclovir

IV ganciclovir at standard dosing

DRUG

Personalised dosing of IV ganciclovir

IV ganciclovir at a personalised dosing calculated using a ganciclovir dosing web app

Trial Locations (7)

1023

NOT_YET_RECRUITING

Starship Children's Hospital, Auckland

2031

NOT_YET_RECRUITING

Sydney Children's Hospital, Sydney

2145

RECRUITING

The Children's Hospital at Westmead, Sydney

3052

RECRUITING

The Royal Children's Hospital, Melbourne

3168

RECRUITING

Monash Children's Hospital, Melbourne

4101

NOT_YET_RECRUITING

Queensland Children's Hospital, Brisbane

6009

RECRUITING

Perth Children's Hospital, Perth

Sponsors
All Listed Sponsors
lead

Murdoch Childrens Research Institute

OTHER